Skye Bioscience, Inc. (SKYE)

Skye Bioscience's stock has been impacted by several events in the past six months. In October 2025, the company reported topline data from its Phase 2a trial, where the monotherapy arm failed to meet its primary endpoint, causing the stock price to plummet. In November 2025, a securities class action lawsuit was filed against the company. In January 2026, Skye announced a collaboration with Halozyme Therapeutics and presented preclinical data on nimacimab. In February 2026, positive interim 52-week data from the Phase 2a extension study was reported. In March 2026, the company reported its financial results, initiated a higher-dose CBeyond Expansion Study, and received FDA feedback. In April 2026, the first patient was treated in the higher-dose expansion study, and Skye presented at the GLP-1-Based Therapeutics Summit. Overall, the stock has experienced a significant decline of 57.80% in the past six months.

Skye Bioscience's products are not subject to seasonal demand patterns. Demand is primarily driven by clinical trial progress, regulatory approvals, and market adoption.

Skye Bioscience, Inc. is a clinical-stage biotechnology company focused on developing treatments for obesity, overweight, and metabolic diseases. The company's lead product candidate is nimacimab, an antibody targeting cannabinoid receptor 1 (CB1), being developed as a potential anti-obesity therapy, either alone or with GLP-1 receptor agonists.

Skye Bioscience, Inc. is headquartered in San Diego, California, United States.

Skye Bioscience's brand reputation has been affected by clinical trial outcomes and legal actions. The failure of nimacimab as a monotherapy and the subsequent lawsuit negatively impacted its reputation. However, positive data from the combination arm of the Phase 2a extension study and a "Market Outperform" rating from Citizens may be helping to rebuild confidence.

Skye Bioscience has a diverse ownership structure, including institutional owners like 5AM Venture Management, Versant Venture Management, Baker Bros. Advisors Lp, and Vanguard Group Inc. Individual owners include Andrew Schwab and CEO Punit Dhillon. The general public holds a 14% stake, while private equity firms hold a 38% stake.